Medtronic has reported net sales of $8.57bn for the first quarter of fiscal year 2026 (Q1 FY26) ended 25 July 2025, an 8.38% increase compared to $7.91bn for the same quarter in FY25.
The healthcare technology company achieved a net income of $1.04bn for Q1 FY26, which remained unchanged from the respective quarter in the previous year.
Medtronic reported an income before tax of $1.3bn for Q1 FY26, a 2.68% increase compared to $1.26bn for the same quarter in FY25.
Medtronic chairman and CEO Geoff Martha said: “We delivered another consistent quarter of mid-single digit organic revenue growth, with broad strength from several innovative product categories, including Pulsed Field Ablation, Transcatheter Valves, Neuromodulation, Diabetes, and Leadless Pacing.
“We’re confident and well-positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers.”
Medtronic’s cardiovascular segment reported revenues of $3.28bn for Q1 FY26, a 9.3% increase from $3bn in the same quarter the prior year.
The company’s neuroscience unit reported revenues of $2.41bn for Q1 FY26, which grew by 4.3% from $2.31bn in Q1 FY25.
Its medical surgical segment achieved revenues of $2.08bn in Q1 FY26, up 4.4% from $1.99bn for the same quarter in FY25.
The healthcare technology company’s diabetes unit reported revenues of $721m in Q1 FY26, an 11.5% rise compared to $647m from the same quarter last year.
Medtronic has raised its FY26 earnings per share (EPS) guidance, attributed to a reduced potential impact from tariffs, now estimated at around $185m.
Medtronic chief financial officer Thierry Piéton said: “As a result of our Q1 EPS outperformance and improved tariff impact assumption, we are raising our full-year EPS guidance.
“Our confidence continues to increase as we advance our revenue growth drivers and execute on efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth, and increase our growth investments in R&D, sales, and marketing, all with a deliberate focus on creating long-term shareholder value.”
